Ipsen

R&D

Ipsen on neurotoxin research: the pharmaphorum podcast

For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a particular focus on Botulinum neurotoxins.

News

Ipsen launches new syringe for rare disease blockbuster

Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU.

News

Ipsen to buy rare disease firm Clementia for up to $1.31bn

France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.

News

Chinese patients to get new drugs before UK after Brexit - s...

US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, the CEO of French pharma Ipsen has said in an interview.

News